<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309569</url>
  </required_header>
  <id_info>
    <org_study_id>ABCSG-7</org_study_id>
    <nct_id>NCT00309569</nct_id>
  </id_info>
  <brief_title>Randomized Study Comparing Pre- and Postoperative Vs. Conventional Adjuvant Treatment in Receptor-Negative Patients</brief_title>
  <official_title>A Randomized Phase III Study Comparing Pre- and Postoperative Vs. Conventional Adjuvant Treatment Hormone Receptor-Negative Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austrian Breast &amp; Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Austrian Breast &amp; Colorectal Cancer Study Group</source>
  <brief_summary>
    <textblock>
      Primarily, this clinical investigation compared overall survival and recurrence-free survival
      in patients with hormone receptor-negative breast cancer treated with pre- and postoperative
      chemotherapy vs. conventional postoperative treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 1991</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of breast-conserving procedures</measure>
  </secondary_outcome>
  <enrollment>480</enrollment>
  <condition>Early Stage Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with bioptically verified breast cancer

          -  Estrogen receptor-negative status

          -  Age: &lt; 70 years

          -  WHO Performance Status &lt; 2

          -  Laboratory parameters

               1. hematopoiesis: &gt; 3500/l leukocytes, &gt; 100,000/l thrombocytes

               2. renal function: creatinin &lt; 1.5mg%

               3. hepatic function: GOT  2.5 x UNL

               4. bilirubin: &lt; 2.0 mg %

               5. metabolic parameters: Na, Ca, K in normal range

          -  &lt;/= 4 weeks interval since surgery

          -  Informed consent

        Exclusion Criteria:

          -  Patients with locally inoperable cancer, M1

          -  Other preoperative tumor-specific radiotherapy, chemotherapy or endocrine treatment

          -  Pregnancy or lactation

          -  General contraindication against cytostatic treatment

          -  T4 cancer; inflammatory disease, simultaneous or sequential bilateral breast cancer

          -  Lacking compliance or understanding of disease

          -  Serious concomitant disease

          -  Second carcinoma or status post second carcinoma (except for treated squamous cell
             carcinoma of the skin or cervical carcinoma in situ)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raimund Jakesz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <link>
    <url>http://www.abcsg.at</url>
  </link>
  <verification_date>October 1999</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2006</study_first_submitted>
  <study_first_submitted_qc>March 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>March 31, 2006</last_update_submitted>
  <last_update_submitted_qc>March 31, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2006</last_update_posted>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Fluorouracil</keyword>
  <keyword>Epirubicine</keyword>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

